The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 28185720 |
42 |
Discovery of phenyl acetamides as potent and selective GPR119 agonists. |
Merck |
| 27560285 |
28 |
Discovery of novel xanthine compounds targeting DPP-IV and GPR119 as anti-diabetic agents. |
Institute Of Materia Medica |
| 27825553 |
18 |
Novel 5-nitropyrimidine derivatives bearing endo-azabicyclic alcohols/amines as potent GPR119 agonists. |
Jiangxi University Of Traditional Chinese Medicine |
| 27326330 |
51 |
Design and Synthesis of 2-Alkylpyrimidine-4,6-diol and 6-Alkylpyridine-2,4-diol as Potent GPR84 Agonists. |
East China Normal University |
| 27390068 |
22 |
Design and synthesis of 1H-pyrazolo[3,4-c]pyridine derivatives as a novel structural class of potent GPR119 agonists. |
Taisho Pharmaceutical |
| 26512410 |
8 |
G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges. |
Sanofi-Aventis Deutschland |
| 26433449 |
29 |
Discovery of the oxazabicyclo[3.3.1]nonane derivatives as potent and orally active GPR119 agonists. |
Merck Research Laboratory |
| 26288697 |
41 |
Design of Potent and Orally Active GPR119 Agonists for the Treatment of Type II Diabetes. |
Merck Research Laboratories |
| 26048791 |
93 |
Discovery of a novel trans-1,4-dioxycyclohexane GPR119 agonist series. |
Arena Pharmaceuticals |
| 25286150 |
75 |
Circumventing seizure activity in a series of G protein coupled receptor 119 (GPR119) agonists. |
Astrazeneca |
| 25082125 |
12 |
Synthesis and biological evaluation of thienopyrimidine derivatives as GPR119 agonists. |
Korea Research Institute Of Chemical Technology |
| 25088191 |
77 |
Discovery and optimization of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonists. |
Arena Pharmaceuticals |
| 25455488 |
46 |
Novel tricyclic pyrazolopyrimidines as potent and selective GPR119 agonists. |
Genomics Institute Of The Novartis Research Foundation |
| 25208139 |
40 |
Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119. |
Departments Of Discovery Chemistry, Metabolic Diseases, Lead Evaluation, Computer-Assisted Drug Design, Discovery Toxicology, Exploratory Clinical And Translational Research, And Pharmaceutical Candi |
| 24755425 |
22 |
Synthesis and structure-activity relationship of dihydrobenzofuran derivatives as novel human GPR119 agonists. |
Bristol-Myers Squibb |
| 24751443 |
52 |
Discovery of structurally novel, potent and orally efficacious GPR119 agonists. |
Genomics Institute Of The Novartis Research Foundation |
| 24440299 |
48 |
Discovery and optimization of 5-(2-((1-(phenylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)oxy)pyridin-4-yl)-1,2,4-oxadiazoles as novel gpr119 agonists. |
Amgen |
| 24508142 |
26 |
Discovery of a novel series of indoline carbamate and indolinylpyrimidine derivatives as potent GPR119 agonists. |
Takeda Pharmaceutical |
| 24332491 |
24 |
Discovery and optimization of N-(3-(1,3-dioxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yloxy)phenyl)benzenesulfonamides as novel GPR119 agonists. |
Amgen |
| 23648181 |
31 |
Discovery and optimization of arylsulfonyl 3-(pyridin-2-yloxy)anilines as novel GPR119 agonists. |
Amgen |
| 23628336 |
72 |
Conformational restriction in a series of GPR119 agonists: differences in pharmacology between mouse and human. |
Astrazeneca |
| 23357035 |
19 |
Synthesis and biological evaluation of novel 2,4-disubstituted quinazoline analogues as GPR119 agonists. |
Kangwon National University |
| 23384387 |
4 |
Novel acylethanolamide derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased neuropeptide Y (NPY). |
Hebrew University Of Jerusalem |
| 23374864 |
9 |
Synthesis and biological evaluation of 5-nitropyrimidine analogs with azabicyclic substituents as GPR119 agonists. |
College Of Pharmacy Of Kangwon National University |
| 24900551 |
14 |
Modulators of the GPR119 Receptor for the Treatment of Metabolic Syndrome. |
Dart Neuroscience |
| 23234271 |
74 |
Design and synthesis of diazatricyclodecane agonists of the G-protein-coupled receptor 119. |
Pfizer |
| 23177788 |
9 |
From partial to full agonism: identification of a novel 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole as a full agonist of the human GPR119 receptor. |
Pfizer |
| 22545772 |
100 |
Use of small-molecule crystal structures to address solubility in a novel series of G protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation. |
Astrazeneca |
| 24900416 |
25 |
GPR119 Modulators for the Treatment of Diabetes, Obesity, and Related Diseases: Patent Highlight. |
TBA |
| 23214471 |
56 |
Discovery of 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines as orally available G protein-coupled receptor 119 agonists. |
Glaxosmithkline |
| 23211099 |
4 |
Identification of new potent GPR119 agonists by combining virtual screening and combinatorial chemistry. |
Boehringer Ingelheim Pharma |
| 22533875 |
11 |
Mitigating heterocycle metabolism in drug discovery. |
Amgen |
| 22765901 |
43 |
Synthesis and SAR studies of bicyclic amine series GPR119 agonists. |
Sanwa Kagaku Kenkyusho |
| 22061639 |
54 |
Discovery, optimisation and in vivo evaluation of novel GPR119 agonists. |
Astrazeneca |
| 22365911 |
3 |
Synthesis and structure-activity relationship of 4-amino-2-phenylpyrimidine derivatives as a series of novel GPR119 agonists. |
Astellas Pharma |
| 22264481 |
58 |
Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile. |
Arena Pharmaceuticals |
| 21536438 |
74 |
Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes. |
Merck Research Laboratories |
| 21444206 |
53 |
Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control. |
Arena Pharmaceuticals |
| 21273063 |
100 |
Design of potent and selective GPR119 agonists for type II diabetes. |
Merck |
| 21361292 |
18 |
Activation of the G-protein-coupled receptor 119: a conformation-based hypothesis for understanding agonist response. |
Pfizer |
| 21310611 |
16 |
Design and evaluation of a 2-(2,3,6-trifluorophenyl)acetamide derivative as an agonist of the GPR119 receptor. |
Pfizer |
| 20227877 |
29 |
2,5-Disubstituted pyridines as potent GPR119 agonists. |
Glaxosmithkline |
| 18698756 |
28 |
Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119. |
Arena Pharmaceuticals |
| 28408218 |
21 |
Synthesis and biological evaluation of pyrimidine derivatives with diverse azabicyclic ether/amine as novel GPR119 agonist. |
Jiangxi University Of Traditional Chinese Medicine |
Search and Browse
